The pharmacist’s role in managing chronic kidney disease: Intervening today can improve outcomes in your patients (October 13, 2021)
This webinar was hosted by CPhA on behalf of AstraZeneca. The content was developed by the speaker and is not accredited.
Michael Boivin, BSc. Phm, RPh, CDE, CTE
Clinical pharmacist consultant and president, CommPharm Consulting Inc.
Download slide deck
Pharmacists play a vital role in assessing risk of chronic kidney disease (CKD) in their patients, and earlier intervention can significantly impact patient outcomes. Understanding new practice and guidance changes following outcomes from major cardio-renal studies, including DECLARE, DAPA-HF and DAPA-CKD, means that prescribers, endocrinologists, cardiologists and nephrologists may initiate SGLT2i in patients with and without diabetes. Community pharmacists, renal pharmacy networks, family heath teams, primary care networks and certified diabetes educators may help identify patients at risk earlier to impact patient health outcomes in the management of CKD.